16 / 56
Tomo VI Vol. V N˚1-2-3 · 2014 · Santiago - Chile
1. Shields CL, Shields JA. Basic understanding
of current classification and management
of Retinoblastoma. Curr Opin Ophtalmol
17:228–234.
2. Trincado A, López JP, González M, et cols.
Retinoblastoma en pediatría, experiencia
en un hospital pediátrico. Rev Chil Pediatr
2008; 79 (6): 614-622.
3. Xu, X. L. et al. Nature
http://dx.doi.org/10.1038/nature13813 (2014).
4. Chial H. (2008) Tumor suppressor (TS)
genes and the two-hit hypothesis. Nature
Education 1(1)
5. Benavente CA, Myer MA. Genetics and
Epigenetics of Human Retinoblastoma. Annu.
Rev. Pathol. Mech. Dis. 2015. 10:547–62
6. Grossniklaus HE. Retinoblastoma. Fifty Years of
Progress. The LXXI Edward Jackson Memorial
Lecture. Am J Ophthalmol 2014;158:875–891.
7. Murphree AL Intraocular Retinoblastoma:
the Case for a New Group Classification.
Ophthalmol Clin N Am 18 (2005) 41 – 53
8. Kim JW, Singh AD. Differential Diagnosis
of Leukocoria. Clinical Ophthalmic
Oncology2015: Retinoblastoma, 13DOI
10.1007/978-3-662-43451-2_2.
9. Abramson DH. Retinoblastoma: Saving Life
with Vision. Annu. Rev. Med. 2014. 65:171–84
10. Abramson DH, et cols. Phase I/II Study
of Direct Intraarterial (Ophthalmic Artery)
Chemotherapy with Melphalan for
Intraocular Retinoblastoma. Ophthalmology
2008;115:1398–1404
11. Shields CL, Shields JA, et cols. Intra-arterial
Chemotherapy for Retinoblastoma in 70
Eyes. Outcomes Based on the International
Classification of Retinoblastoma.
http://dx.doi.
org/10.1016/j.ophtha.2014.01.026
BIBLIOGRAFÍA